-
A number of pharmaceutical companies' API projects have attracted investors' attention, involving ibuprofen, montmorillonite and other APIs
Time of Update: 2023-02-03
At the same time, some of the API drugs that have recently set off a rush of buying have attracted the attention of investors, and in recent days, many pharmaceutical companies, including Rundu Co.
-
More than 100 million yuan of hypoglycemic drug market, ushered in another evaluated pharmaceutical company!
Time of Update: 2023-02-03
On January 5, Hanyu Pharmaceutical issued an announcement that the company received the "Drug Registration Certificate" issued by the State Medical Products Administration, and the company's hypoglycemic drug "vildagliptin tablets" was approved for marketing and deemed to have passed the consistency evaluation.
-
Since December, 8 drugs at home and abroad have been approved for marketing
Time of Update: 2023-02-03
Since December, a total of 8 drugs at home and abroad have been approved for marketing. As drugs become available, patients will have more drug options. Let's take a look at these 8 drugs together. O
-
Domestic innovative medical device R&D and industrialization has entered the fast lane!
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Driven by multiple advantages such as encouraging innovative medical devices, easing the marginal of centralized procurement policies, and supporting equipment renewal with financial discounted interest loans, the development of the domestic medical device industry is accelerating, and domestic medical devices have gradually begun to usher in a harvest period, and products are constantly on the market.
-
Beijing adjusts the reimbursement standards for basic medical insurance medical materials All individual expenses below 1,000 yuan are included
Time of Update: 2023-02-03
According to the website of the Beijing Municipal Medical Security Bureau, the Beijing Municipal Medical Security Bureau recently issued a notice on adjusting the reimbursement standards for medical materials for basic medical insurance.
-
In 2022, there will be frequent personnel changes in pharmaceutical companies, with more than 250 senior executives leaving
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];The "big change" of management is a microcosm of the frequent changes in senior management in the pharmaceutical industry.
js?cdnversion='+~(-new Date()/36e5)];The "big change" of management is a microcosm of the frequent changes in senior management in the pharmaceutical industry.
-
The internationalization of domestic innovative drugs has accelerated, and a number of new drugs have been approved by the FDA for clinical trials
Time of Update: 2023-02-03
, Ltd. announced that the company's self-developed innovative antibody conjugate drug (ADC) RC108 for injection has obtained the clinical trial approval of the US Food and Drug Administration (FDA) to carry out clinical research in patients with solid tumors with positive c-Met expression.
-
Review of the top 5 major events in the pharmaceutical industry in 2022
Time of Update: 2023-02-03
Dental implant collection landing On August 18, the National Health Insurance Administration issued the Notice on Carrying out Special Governance of Oral Implant Medical Service Charges and Consumables Prices (Draft for Comments), which mentioned the establishment of an interprovincial procurement alliance for dental implant consumables.
-
The development focus of traditional Chinese medicine innovative pharmaceutical enterprises, long-term opportunities are emerging
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Traditional Chinese medicine is one of the characteristics of Chinese medicine, in recent years, the approval speed of domestic innovative Chinese medicine drugs has increased significantly, and Chinese medicine innovative drugs and exclusive varieties have a greater competitive advantage in medical insurance procurement, in this context, some pharmaceutical companies have begun to take traditional Chinese medicine innovative drugs as the focus of the company's development.
-
In 2022, Mindray Medical Reception Institutions exceeded 5,000
Time of Update: 2023-02-03
According to the data, Mindray exceeded 270 blank customers in high-end hospitals and 350 horizontal customers in the first three quarters of 2022 in the life information and support production line.
-
Future strategic planning of pharmaceutical companies, new drug research and development into the focus of development!
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];On January 4, Genting Xinyao released its strategic plan for the next two years and beyond, the company will further transform into a comprehensive biopharmaceutical company, realize the whole industry chain layout, including strong independent R&D and licensing capabilities, clinical development capabilities, and large-scale production and commercialization capabilities.
-
The development prospects of the domestic pharmaceutical and biological innovation track are promising, and the investment and financing are active!
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Looking back on 2022, investment and financing in the field of medicine and biology can be said to be very active.
js?cdnversion='+~(-new Date()/36e5)];Looking back on 2022, investment and financing in the field of medicine and biology can be said to be very active.
-
Since December, financing incidents in the medical and health sector have been frequent
Time of Update: 2023-02-03
Recently, Core Medical, a developer of high-end innovative medical device products, announced the completion of hundreds of millions of yuan in Series C financing, which will be mainly used to accelerate the R&D, clinical and commercialization layout of product lines and build an innovative active plant intervention platform.
-
28 proprietary Chinese medicines lit up! 6 varieties of more than 1 billion lead the way, and 17 exclusive varieties dominate the screen
Time of Update: 2023-02-03
The 17 proprietary Chinese medicines are exclusive varieties, including Yangzijiang Pharmaceutical's Lanqin Oral Liquid, Jichuan Pharmaceutical's Pudi Blue Anti-inflammatory Oral Liquid, Sanli Pharmaceutical's Open Throat Sword Spray, Sunflower Pharmaceutical's Pediatric Lung Fever, Cough and Asthma Oral Liquid, and Darentang's Clear Throat Drop Pill.
-
Circular of the State Food and Drug Administration on the Results of National Medical Device Supervision and Sampling (No. 4) (No. 63 of 2022)
Time of Update: 2023-02-03
0ml/pc/box DANAE Line Z1 2021-03-26 C1053J1 Beijing Municipal Drug Administration China Academy of Food and Drug Control Free sodium hyaluronate content serial number Label the product name Spot checked Indicate the medical device registrant and recordation holder Specifications and models Date of manufacture/batch number/factory number sampling Inspection Non-compliance with standard provisions 1 Electric wheelchair car Shanxi Kangwanjia Medical Equipment Chain Co.
-
2023 Shenzhen Medical Fair
Time of Update: 2023-02-03
cn/shenzhen Address: Room 1003, Building A, Twin Buildings, No. 668 Xin Brick Road, Songjiang District, Shanghai Contact number: 18721265877 Contact WeChat: shenzhenexpo Contact person: Mr. Shen The 40th Shenzhen International Medical Equipment Exhibition 2023 will be held in Shenzhen World Exhibition and Convention Center on August 29-31, covering medical electronics and medical film Like equipment, intelligent medical care, ward nursing and auxiliary equipment, medical dressings, in vitro diagnostic reagents, optical first aid, rehabilitation nursing and medical informatization, etc.
-
The State Administration for Market Regulation launched a national special action to stabilize the price and quality of epidemic-related drugs and medical supplies
Time of Update: 2023-02-03
According to the news of the State Administration for Market Regulation on the 4th, a few days ago, the State Administration for Market Regulation issued the "Notice of the State Administration for M
-
In 2023, favorable policies will continue to increase the weight of traditional Chinese medicine, and the long-term opportunities of the sector will be optimistic by institutions
Time of Update: 2023-02-03
On the trading day of the New Year in 2023, the traditional Chinese medicine sector changed in early trading, and in the morning of January 3, Fangsheng Pharmaceutical and Zhongsheng Pharmaceutical touched the limit of increase, and individual stocks such as Kangbei, Hongri Pharmaceutical, and Kunming Pharmaceutical followed suit.
-
In 2023, pharmaceutical companies will start "buying, buying, buying" again!
Time of Update: 2023-02-03
On the same day, Fengyuan Pharmaceutical disclosed its plan to acquire assets, and the company purchased 100% of the equity of Tigermed Technology held by Tigermed Biologics by issuing shares and raised supporting funds.
-
On-site negotiations on the adjustment of the national medical insurance drug list involve hundreds of clinical drugs
Time of Update: 2023-02-03
Since the establishment of the National Health Insurance Administration, the list of medical insurance drugs has been adjusted for four consecutive years, and a total of 507 new drugs and good drugs have been included and 391 drugs with uncertain efficacy have been transferred.